GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HLB Life Science Co 067630.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

2,585

+1.17%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About HLB Life Science Co

Its shares trade on KOSDAQ under the ticker 067630.KQ. It has been listed since 25 November 2008. In the fiscal year to 31 December 2025, it reported revenue of ₩45.75bn and a net loss of ₩99.79bn. At that date it held total assets of ₩478.09bn and shareholders' equity of ₩297.35bn.

HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-11-25. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. The company is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
25 Nov 2008
Website
hlb-ls.com ↗

Leadership

Pay as last reported

  • Sang Wu NamCo-Chief Executive Officer, Director, since 2022
  • Sang Hwan KimVice Chairman of the Board, since 2013
  • Seok Gon ChoiVice Chairman
  • Seong Nam ChoiVice President
  • Mr. Sang Min LeeManaging Director, since 2012
  • Hak Jeon KimManaging Director, since 2013
  • Mo Seok LeeHead of Planning, Director
  • Seong Ho YimInternal Auditor
  • Chang Hyeon KimDirector
  • Seong Hyeon LeeDirector
  • Hyeong Heum ShimDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • HLB Life Science Co Ltd possesses several strengths that contribute to its success in the life science industry. These strengths include:

Weaknesses

  • Despite its strengths, HLB Life Science Co Ltd also faces certain weaknesses that pose challenges to its growth and competitiveness. These weaknesses include:

Opportunities

  • HLB Life Science Co Ltd can leverage a number of opportunities in the market to drive growth and expansion. These opportunities include:

Threats

  • HLB Life Science Co Ltd faces various threats that can impact its business operations and market position. These threats include:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.